[Hinews] CHICAGO — Boditech Med, a South Korean leader in point-of-care diagnostics, showcased an extensive lineup of in-vitro diagnostic products at the Association for Diagnostics & Laboratory Medicine (ADLM) 2025 conference, held from July 29 to July 31 in Chicago. The annual North American event, which draws over 20,000 professionals and 800 companies, highlighted cutting-edge topics such as genomics-based personalized diagnostics, environmental toxin analysis, and artificial intelligence in healthcare.

Boditech Med spotlighted its flagship automated immunoassay platform, AFIAS, featuring key diagnostic assays including IGRA-TB for latent tuberculosis, PENKID for acute kidney injury prediction, TDM for therapeutic drug monitoring, HOMA-IR for insulin resistance, and vitamin D testing. These solutions address critical needs in clinical diagnostics, offering rapid and reliable results for healthcare providers.

Boditech Med headquarters (Photo courtesy of Boditech Med)
Boditech Med headquarters (Photo courtesy of Boditech Med)


The company also unveiled its veterinary diagnostic portfolio, including the automated AFIAS-VET and the manual VETCHROMA 3, both immunoassay-based systems designed for flexible use in various settings. Additionally, Boditech displayed UROCHROMA, a urine analysis device, and VETCHEMIS, a whole-blood biochemistry analyzer, underscoring its commitment to diverse diagnostic applications.

Boditech Med aims to leverage ADLM 2025 to accelerate its expansion in North and South American markets. After experiencing significant growth in the Americas during the pandemic, followed by a period of adjustment, the company is positioning 2025 as a pivotal year for rebound. Plans include strengthening sales efforts and expanding its partner network across the region.
On the eve of the conference, Boditech hosted its third South America Distributor Conference, reinforcing ties with regional partners to bolster its presence in Latin America.

키워드

#바디텍메드#ADLM2025
저작권자 © Hinews 무단전재 및 재배포 금지
ad